Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 79-112

  Michaelides, Michael ^a   Albert, Daniel H ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 869 discovery in clinical trials for cancer treatment; Alternate bicyclic heterocyclopyrimidines; Road to ABT 869 multitargeted receptor tyrosine kinase inhibitor

Indexed keywords

EID: 84863768727     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch4     Document Type: Chapter

References (58)

1. Akritopoulou-Zanze, I., Albert, D. H., Bousquet, P. F., et al. (2007). Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c ]pyrazoles as multitargeted receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 17 (11), 3136-3140.
2. Albert, D. H., Tapang, P., Magoc, T. J., et al. (2006). Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 5 (4), 995-1006.
3. Arnold, L. D., Calderwood, D. J., Dixon, R. W., et al. (2000). Pyrrolo[2,3-d ]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck I. Bioorg Med Chem Lett. 10 (19), 2167-2170.
4. Bergers, G., and Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3 (6), 401-410.
5. Bergers, G., Javaherian, K., Lo, K. M., et al. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284 (5415), 808-812.
6. Bergers, G., Song, S., Meyer-Morse, N., et al. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 111 (9), 1287-1295.
7. Bergström, C. A., Wassvik, C. M., Johansson, K., et al. (2007). Poorly soluble marketed drugs display solvation limited solubility. J Med Chem. 50 (23), 5858-5862.
8. Bousquet, P. F. (2002). Bone marrow recovery following cyclophosphamide ablation. (Unpublished results.)
9. Burchat, A. F., Calderwood, D. J., Friedman, M. M., et al. (2002). Pyrazolo[3,4-d ] pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg Med Chem Lett. 12 (12), 1687-1690.
10. Camps, J. L., Chang, S. M., Hsu, T. C., et al. (1990). Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA. 87 (1), 75-79.
11. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat Med. 9 (6), 653-660.
12. Curtin, M. L., Frey, R. R., Heyman, H. R., et al. (2004). Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 14 (17), 4505-4509.
13. Cusack, K. P., Arnold, L. D., Barberis, C. E., et al. (2004). A 13C NMR approach to categorizing potential limitations of alpha,beta-unsaturated carbonyl systems in drug-like molecules. Bioorg Med Chem Lett. 14 (22), 5503-5507.
14. Dai, Y., Guo, Y., Frey, R. R., et al. (2005). Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem. 48 (19), 6066-6083.
15. Dai, Y., Hartandi, K., Ji, Z., et al. (2007). Discovery of N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N ′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 50 (7), 1584-1597.
16. Dai, Y., Hartandi, K., Soni, N. B., et al. (2008). Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett. 18 (1), 386-390.
17. Dinges, J., Akritopoulou-Zanze, I., Arnold, L. D., et al. (2006a). Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c ]pyrazoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 16 (16), 4371-4375.
18. Dinges, J., Ashworth, K. L., Akritopoulou-Zanze, I., et al. (2006b). 1,4-Dihydroindeno[1,2-c ]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 16 (16), 4266-4271.
19. Dinges, J., Albert, D. H., Arnold, L. D., et al. (2007). 1,4-Dihydroindeno[1,2-c ]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel. J Med Chem. 50 (9), 2011-2029.
20. Dixon, J. A., Brennan, C., Miranda, K., et al. (2005). Bayer Pharmaceuticals Corporation, assignee. Preparation of pyrrolotriazine urea derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis. WO2005121147. 22 December 2005.
21. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat Med. 9 (6), 669-676.
22. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1 (1), 27-31.
23. Folkman, J. (1996). Angiogenesis and angiogenesis inhibition: an overview. In : I. D. Goldberg and E. M. Rosen (eds.) Regulation of Angiogenesis, pp. 1-8. Basel, Switzerland : Birkhauser Verlag.
24. Frey, R. R., Curtin, M. L., Albert, D. H., et al. (2008). 7-Aminopyrazol[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem. 51 (13), 777-3787.
25. Gerber, H.-P., and Ferrara, N. (2003). The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 81 (1), 20-31.
26. Glaser, K. (2008). Effect of ABT-869 on the proliferation of mast and B cells expressing FLT3-WT or mutated FLT3. (Unplublished results.)
27. Gordon, M. S., Margolin, K., Talpaz, M., et al. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 19 (3), 843-850.
28. Gorre, M. E., Mohammed, M., Ellwood, K., et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293 (5531), 876-880.
29. Gracias, V., Ji, Z., Akritopoulou-Zanze, I., et al. (2008). Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 18 (8), 2691-2695.
30. Guo, J., Marcotte, P. A., McCall, J. O., et al. (2006). Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 5 (4), 1007-1013.
31. Gupta, N., Goh, B.-C., Soo, R., et al. (2007a). Pharmacokinetic comparison of multiple receptor tyrosine kinase inhibitor ABT-869 in Asian and Caucasian populations. In :AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, San Francisco, CA, p. C 148.
32. Gupta, N., Goh, B.-C., Soo, R., et al. (2007b). Relative bioavailability study of multiple receptor tyrosine kinase inhibitor ABT-869 for comparison of oral solution and Meltrex ® tablet formulations. In : AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, San Francisco, CA, p. C149.
33. Heyman, H. R., Frey, R. R., Bousquet, P. F., et al. (2007). Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett. 17 (5), 1246-1249.
34. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307 (5706), 58-62.
35. Jasinghe, V. J., Xie, Z., Zhou, J., et al. (2008). ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for hepatocellular carcinoma (HCC) in vivo. J Hepatol. 49 (6), 985-997.
36. Ji, Z., Ahmed, A. A., Albert, D. H., et al. (2006). Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 16 (16), 4326-4330.
37. Ji, Z., Ahmed, A. A., Albert, D. H., Bouska, J. J., et al. (2008). 3-Amino-benzo[ d ] isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases. J Med Chem. 51 (5), 1231-1244.
38. Leung, D. W., Cachianes, G., Kuang, W. J., et al. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246 (4935), 1306-1309.
39. Li, L., Lin, X., Shoemaker, A. R., et al. (2006). Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res. 12 (15), 4747-4754.
40. Lyman, S. D., and Jacobsen, S. E. W. (1998). c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 91 (4), 1101-1134.
41. Ma, W., Tan, J., Matsumoto, H., et al. (2001). Adult tissue angiogenesis: evidence for negative regulation by estrogen in the uterus. Mol Endocrinol. 15 (11), 1983-1992.
42. Mandli, M., and Darbyshire, J. (2006). Protein binding of [3H]A-741439 to mouse, rat, dog, monkey and human plasma. (Unpublished results.)
43. Marsh, K. C. (2003). Preclinical pharmacokinetics of ABT-869. (Unpublished results.)
44. McKenna, H. J., Stocking, K. L., Miller, R. E., et al. (2000). Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 95 (11), 3489-3497.
45. Miyazaki, Y., Matsunaga, S., Tang, J., et al. (2005). Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett. 15 (9), 2203-2207.
46. Miyazaki, Y., Nakano, M., Sato, H., et al. (2007a). Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c ]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. Bioorg Med Chem Lett. 17 (1), 250-254.
47. Miyazaki, Y., Tang, J., Maeda, Y., et al. (2007b). Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg Med Chem Lett. 17 (6), 1773-1778.
48. Moset Marina, M., Berlanga, J. M. C., Fernandez, I. F., et al. (2001). BASF Aktiengesellschaft, assignee. Preparation of 2-pyrazolin-5-ones as inhibitors of serine/threonine and tyrosine kinase activity. WO01009121. 8 February 2001.
49. Rafferty, P., Calderwood, D., Arnold, L. D., et al. (2000). BASF Aktiengesellschaft, assignee. Preparation and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors. WO00/075139. 14 December 2000.
50. Sengupta, K., Banerjee, S., Saxena, N., et al. (2003). Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway. Int J Oncol. 22 (3), 609-614.
51. Sepp-Lorenzino, L., Rands, E., Mao, X., et al. (2004). A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. Cancer Res. 64 (2), 751-756.
52. Shankar, D. B., Li, J., Tapang, P., et al. (2007). ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 109 (8), 3400-3408.
53. Stirewalt, D. L., and Radich, J. P. (2003). The role of FLT3 in haematopoietic malignancies . Nat Rev Cancer. 3 (9), 650-665.
54. Tolcher, A. W., O'Leary, J. J., DeBono, J. S., et al. (2002). A Phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR -2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol. 21 Abstract #334.
55. Weisberg, E., Boulton, C., Kelly, L. M., et al. (2002). Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1 (5), 433-443.
56. Zhou, J., Bi, C., Janakakumara, J. V., et al. (2009). Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 113 (7), 4052-4062.
57. Zhou, J., Khng, J., Jasinghe, V. J., et al. (2008b). In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor . Leuk Res. 32 (7), 1091-1100.
58. Zhou, J., Pan, M., Xie, Z., et al. (2008c). Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia. 22 (1), 138-146.